{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:15:05Z","timestamp":1793888105229,"version":"4.8.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Relationship between cancer cell glycolysis and the landscape of tumor immune microenvironment in human cancers was investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Forty-one fresh lung adenocarcinoma (ADC) tissues were analyzed using flow cytometry for comprehensive immunoprofiling. Formalin-fixed tissues were immunostained for hexokinase-2 (HK2) to assess cancer cell glycolysis. For validation, formalin-fixed tissues from 375 lung ADC, 118 lung squamous cell carcinoma (SqCC), 338 colon ADC, and 78 lung cancer patients treated with anti-PD-1\/PD-L1 immunotherapy were immunostained for HK2, CD8, and FOXP3.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Based on immunoprofiling of lung ADC, HK2 tumor expression was associated with the composition of lymphoid cells rather than myeloid cells. High HK2 tumor expression was associated with immunosuppressive\/pro-tumorigenic features, especially decreased ratio of CD8\u2009+\u2009T-cells to Tregs (rho\u2009=\u2009\u22120.415, <jats:italic>P<\/jats:italic>\u2009=\u20090.012). This correlation was also confirmed in four different cohorts including lung ADC and SqCC, colon ADC, and the immunotherapy cohort (rho\u2009=\u2009\u22120.175~-0.335, all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). A low CD8\u2009+\u2009T-cell to Treg ratio was associated with poor progression-free survival and overall survival in lung SqCC patients, and a shorter overall survival in the immunotherapy cohort (all, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>An increase in HK2 expression may contribute to shaping the immunosuppressive\/pro-tumorigenic tumor microenvironment by modulating the CD8\u2009+\u2009T-cell to Treg ratio. Targeting tumor HK2 expression might be a potential strategy for enhancing anti-tumor immunity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10239-6","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T20:17:19Z","timestamp":1667333839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["High tumor hexokinase-2 expression promotes a pro-tumorigenic immune microenvironment by modulating CD8+\/regulatory T-cell infiltration"],"prefix":"10.1186","volume":"22","author":[{"given":"Sehui","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaemoon","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Geun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeemin","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miso","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doo Hyun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Kyung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"issue":"17","key":"10239_CR1","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1001\/jama.2017.14155","volume":"318","author":"SL Topalian","year":"2017","unstructured":"Topalian SL. Targeting Immune Checkpoints in Cancer Therapy. JAMA. 2017;318(17):1647\u20138.","journal-title":"JAMA"},{"issue":"19","key":"10239_CR2","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"11","key":"10239_CR3","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"4","key":"10239_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"issue":"1","key":"10239_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278.","journal-title":"J Immunother Cancer"},{"key":"10239_CR6","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1200\/EDBK_289967","volume":"e40","author":"GG Lagos","year":"2020","unstructured":"Lagos GG, Izar B, Rizvi NA. Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy. Am Soc Clin Oncol Educ Book. 2020;e40:e47-57.","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"10239_CR7","doi-asserted-by":"publisher","unstructured":"Lei Y, Li X, Huang Q, Zheng X, Liu M. Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. Front Oncol. 2021;11(609). https:\/\/doi.org\/10.3389\/fonc.2021.617335.","DOI":"10.3389\/fonc.2021.617335"},{"issue":"1","key":"10239_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","volume":"6","author":"T Tang","year":"2021","unstructured":"Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Therapy. 2021;6(1):72.","journal-title":"Signal Transduct Target Therapy"},{"key":"10239_CR9","doi-asserted-by":"publisher","unstructured":"Nguyen KB, Spranger S. Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling. J Cell Biol. 2019;219(1). https:\/\/doi.org\/10.1083\/jcb.201908224.","DOI":"10.1083\/jcb.201908224"},{"issue":"1","key":"10239_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.immuni.2020.06.016","volume":"53","author":"S Kumagai","year":"2020","unstructured":"Kumagai S, Togashi Y, Sakai C, Kawazoe A, Kawazu M, Ueno T, Sato E, Kuwata T, Kinoshita T, Yamamoto M, et al. An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. Immunity. 2020;53(1):187\u2013203.e188.","journal-title":"Immunity"},{"issue":"2","key":"10239_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202\u201316.","journal-title":"Cancer Discov"},{"issue":"5","key":"10239_CR12","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","volume":"76","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, et al. STK11\/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016;76(5):999\u20131008.","journal-title":"Cancer Res"},{"issue":"4_suppl","key":"10239_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.2019.37.4_suppl.609","volume":"37","author":"M Marco","year":"2019","unstructured":"Marco M, Chen C-T, Choi S-H, Pelossof R, Shia J, Garcia-Aguilar J. A KRAS mutation is associated with an immunosuppressive tumor microenvironment in mismatch-repair proficient colorectal cancer. J Clin Oncol. 2019;37(4_suppl):609\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"10239_CR14","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/s41467-021-21736-w","volume":"12","author":"I Ischenko","year":"2021","unstructured":"Ischenko I, D\u2019Amico S, Rao M, Li J, Hayman MJ, Powers S, Petrenko O, Reich NC. KRAS drives immune evasion in a genetic model of pancreatic cancer. Nat Commun. 2021;12(1):1482.","journal-title":"Nat Commun"},{"issue":"6","key":"10239_CR15","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015;162(6):1229\u201341.","journal-title":"Cell"},{"issue":"1","key":"10239_CR16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s13046-019-1407-5","volume":"38","author":"S Kim","year":"2019","unstructured":"Kim S, Jang JY, Koh J, Kwon D, Kim YA, Paeng JC, Ock CY, Keam B, Kim M, Kim TM, et al. Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer. J Exp Clin Cancer Res. 2019;38(1):462.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3191","key":"10239_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg O. On the Origin of Cancer Cells. Science. 1956;123(3191):309\u201314.","journal-title":"Science"},{"issue":"1","key":"10239_CR18","doi-asserted-by":"publisher","first-page":"107848","DOI":"10.1016\/j.celrep.2020.107848","volume":"32","author":"L Guerra","year":"2020","unstructured":"Guerra L, Bonetti L, Brenner D. Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy. Cell Rep. 2020;32(1):107848.","journal-title":"Cell Rep"},{"issue":"9","key":"10239_CR19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","volume":"20","author":"RD Leone","year":"2020","unstructured":"Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20(9):516\u201331.","journal-title":"Nat Rev Cancer"},{"key":"10239_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.coi.2020.07.001","volume":"67","author":"M Buszko","year":"2020","unstructured":"Buszko M, Shevach EM. Control of regulatory T cell homeostasis. Curr Opin Immunol. 2020;67:18\u201326.","journal-title":"Curr Opin Immunol"},{"issue":"7740","key":"10239_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41586-018-0846-z","volume":"565","author":"SE Weinberg","year":"2019","unstructured":"Weinberg SE, Singer BD, Steinert EM, Martinez CA, Mehta MM, Mart\u00ednez-Reyes I, Gao P, Helmin KA, Abdala-Valencia H, Sena LA, et al. Mitochondrial complex III is essential for suppressive function of regulatory T cells. Nature. 2019;565(7740):495\u20139.","journal-title":"Nature"},{"issue":"6","key":"10239_CR22","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.immuni.2009.04.014","volume":"30","author":"GM Delgoffe","year":"2009","unstructured":"Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, Worley PF, Kozma SC, Powell JD. The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment. Immunity. 2009;30(6):832\u201344.","journal-title":"Immunity"},{"issue":"8","key":"10239_CR23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.trecan.2017.06.005","volume":"3","author":"H Wang","year":"2017","unstructured":"Wang H, Franco F, Ho P-C. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy. Trends in Cancer. 2017;3(8):583\u201392.","journal-title":"Trends in Cancer"},{"key":"10239_CR24","doi-asserted-by":"publisher","unstructured":"Viola A, Munari F, S\u00e1nchez-Rodr\u00edguez R, Scolaro T, Castegna A. The Metabolic Signature of Macrophage Responses. Front Immunol. 2019;10(1462). https:\/\/doi.org\/10.3389\/fimmu.2019.01462.","DOI":"10.3389\/fimmu.2019.01462"},{"issue":"8","key":"10239_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485\u201398.","journal-title":"Nat Rev Immunol"},{"key":"10239_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC cancer staging manual","author":"MBESBAJCoC Amin","year":"2017","unstructured":"Amin MBESBAJCoC. AJCC cancer staging manual. 2017."},{"key":"10239_CR27","volume-title":"AJCC Cancer Staging Manual","author":"SB Edge","year":"2011","unstructured":"Edge SB. AJCC Cancer Staging Manual. New York: Springer; 2011."},{"issue":"13","key":"10239_CR28","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1158\/1078-0432.CCR-18-3458","volume":"25","author":"J Koh","year":"2019","unstructured":"Koh J, Kim HY, Lee Y, Park IK, Kang CH, Kim YT, Kim JE, Choi M, Lee WW, Jeon YK, et al. IL23-Producing Human Lung Cancer Cells Promote Tumor Growth via Conversion of Innate Lymphoid Cell 1 (ILC1) into ILC3. Clin Cancer Res. 2019;25(13):4026\u201337.","journal-title":"Clin Cancer Res"},{"key":"10239_CR29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.canlet.2020.07.022","volume":"490","author":"R Saleh","year":"2020","unstructured":"Saleh R, Elkord E. FoxP3 + T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets. Cancer Lett. 2020;490:174\u201385.","journal-title":"Cancer Lett"},{"issue":"200","key":"10239_CR30","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):200ra116.","journal-title":"Sci Transl Med"},{"issue":"1","key":"10239_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cmet.2014.05.004","volume":"20","author":"AN Macintyre","year":"2014","unstructured":"Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, Deoliveira D, Anderson SM, Abel ED, Chen BJ, Hale LP, et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 2014;20(1):61\u201372.","journal-title":"Cell Metab"},{"issue":"6","key":"10239_CR32","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.4049\/jimmunol.1003613","volume":"186","author":"RD Michalek","year":"2011","unstructured":"Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, Sullivan SA, Nichols AG, Rathmell JC. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4 + T cell subsets. J Immunol. 2011;186(6):3299\u2013303.","journal-title":"J Immunol"},{"issue":"5","key":"10239_CR33","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, et al. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metab. 2016;24(5):657\u201371.","journal-title":"Cell Metab"},{"issue":"7","key":"10239_CR34","doi-asserted-by":"publisher","first-page":"e1002202","DOI":"10.1371\/journal.pbio.1002202","volume":"13","author":"R Haas","year":"2015","unstructured":"Haas R, Smith J, Rocher-Ros V, Nadkarni S, Montero-Melendez T, D\u2019Acquisto F, Bland EJ, Bombardieri M, Pitzalis C, Perretti M, et al. Lactate Regulates Metabolic and Pro-inflammatory Circuits in Control of T Cell Migration and Effector Functions. PLoS Biol. 2015;13(7):e1002202.","journal-title":"PLoS Biol"},{"issue":"11","key":"10239_CR35","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1158\/0008-5472.CAN-11-1272","volume":"72","author":"A Calcinotto","year":"2012","unstructured":"Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, Cova A, Canese R, Jachetti E, Rossetti M, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res. 2012;72(11):2746\u201356.","journal-title":"Cancer Res"},{"issue":"6","key":"10239_CR36","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1158\/0008-5472.CAN-15-1743","volume":"76","author":"S Pilon-Thomas","year":"2016","unstructured":"Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K, Damaghi M, Wojtkowiak JW, Mul\u00e9 JJ, Ibrahim-Hashim A, et al. Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. Cancer Res. 2016;76(6):1381\u201390.","journal-title":"Cancer Res"},{"issue":"5","key":"10239_CR37","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1021\/acs.nanolett.8b04296","volume":"19","author":"YX Zhang","year":"2019","unstructured":"Zhang YX, Zhao YY, Shen J, Sun X, Liu Y, Liu H, Wang Y, Wang J. Nanoenabled Modulation of Acidic Tumor Microenvironment Reverses Anergy of Infiltrating T Cells and Potentiates Anti-PD-1 Therapy. Nano Lett. 2019;19(5):2774\u201383.","journal-title":"Nano Lett"},{"issue":"51","key":"10239_CR38","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al. Intraepithelial CD8 + tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102(51):18538\u201343.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10239_CR39","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12967-018-1460-4","volume":"16","author":"K Takada","year":"2018","unstructured":"Takada K, Kashiwagi S, Goto W, Asano Y, Takahashi K, Takashima T, Tomita S, Ohsawa M, Hirakawa K, Ohira M. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. J Translational Med. 2018;16(1):86.","journal-title":"J Translational Med"},{"issue":"1","key":"10239_CR40","doi-asserted-by":"publisher","first-page":"15179","DOI":"10.1038\/srep15179","volume":"5","author":"B Shang","year":"2015","unstructured":"Shang B, Liu Y, Jiang S-j, Liu Y. Prognostic value of tumor-infiltrating FoxP3 + regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5(1):15179.","journal-title":"Sci Rep"},{"key":"10239_CR41","doi-asserted-by":"publisher","unstructured":"Kouidhi S, Ben Ayed F, Benammar Elgaaied A. Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy. Front Immunol. 2018;9(353). https:\/\/doi.org\/10.3389\/fimmu.2018.00353.","DOI":"10.3389\/fimmu.2018.00353"},{"issue":"10","key":"10239_CR42","doi-asserted-by":"publisher","first-page":"101042832096528","DOI":"10.1177\/1010428320965284","volume":"42","author":"P Farhadi","year":"2020","unstructured":"Farhadi P, Yarani R, Dokaneheifard S, Mansouri K. The emerging role of targeting cancer metabolism for cancer therapy. Tumor Biology. 2020;42(10):1010428320965284.","journal-title":"Tumor Biology"},{"issue":"9","key":"10239_CR43","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.3390\/ijms22094716","volume":"22","author":"F Ciscato","year":"2021","unstructured":"Ciscato F, Ferrone L, Masgras I, Laquatra C, Rasola A. Hexokinase 2 in Cancer: A Prima Donna Playing Multiple Characters. Int J Mol Sci. 2021;22(9):4716.","journal-title":"Int J Mol Sci"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10239-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10239-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10239-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T20:17:52Z","timestamp":1667333872000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10239-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10239"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10239-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]},"assertion":[{"value":"14 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the World Medical Association Declaration of Helsinki and was approved by the institutional review board (IRB) of Seoul National University Hospital (SNUH) (H-1404-100-572 and H-1905-115-1035). Informed consent for participation in the IHC study only cohorts was waivered by the IRB of Seoul National University Hospital on the basis that this study was a retrospective study using archived material, and did not increase risk to the patients. Fresh tumor samples from 41 lung ADC patients were used for flow cytometry analysis. All patients in this cohort agreed to the sample collection and data analyses. Written informed consent was provided by all participants for this cohort.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}],"article-number":"1120"}}